Company news

Curis, Inc. news in 2022

Curis, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

December 11, 2022

Curis Provides Third Quarter 2022 Business Update

November 8, 2022

Curis Announces Three Presentations at SITC 2022

November 6, 2022

Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022

November 1, 2022

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

October 2, 2022

Curis Announces Date for the 2nd Annual VISTA Symposium

September 18, 2022

FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study

August 29, 2022

FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

August 17, 2022

Curis Reports Second Quarter 2022 Financial Results and Business Update

August 3, 2022

Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

July 28, 2022

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

July 27, 2022

Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress

June 9, 2022

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

June 3, 2022

Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

May 11, 2022

Curis Reports First Quarter 2022 Financial Results and Business Update

May 4, 2022

Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)

April 10, 2022

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

April 3, 2022

Curis Reports Fourth Quarter and Year End 2021 Financial Results

February 23, 2022

Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022

February 16, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with...

January 5, 2022

Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

January 2, 2022

Calls in 2022

Decks in 2022